Search

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Patients with a rare and aggressive form of liposarcoma need treatment advances

Creating an Inclusive Workplace for Employees with Disabilities

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

Supply Chain Scholarship for Cowtribe

A supply chain course we sponsored boosted the career of Latifa Saaka

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

FDA accepts sNDA for children/adolescents with fibrosing ILD

Results for Jardiance® (empaglifozin) | BI US

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Patients with a rare and aggressive form of liposarcoma need treatment advances

Creating an Inclusive Workplace for Employees with Disabilities

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

Supply Chain Scholarship for Cowtribe

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Outlook for Partnering in Animal Health 2024

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF